For the first time a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients one to three years after a heart attack. Because it has been shown previously to reduce the high risk of recurrent events for up to a year following a heart attack, DAPT is considered to be standard therapy during this time period. But whether or not longer term treatment after a year would be also beneficial has been controversial.
AstraZeneca today announced that the Pegasus-TIMI 54 study had successfully reached its primary endpoint.
…
Click here to read the full post on Forbes.
Speak Your Mind